Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
A KurreckM GeisslerU M MartensJ Riera-KnorrenschildJ GreeveA FlorschützS WessendorfT EttrichS KanzlerD NörenbergM SeidenstickerS HeldP Buechner-SteudelJ AtzpodienV HeinemannS StintzingT SeufferleinA TannapfelA C Reinacher-SchickDominik Paul ModestPublished in: Journal of cancer research and clinical oncology (2020)
BRAF-MT patients derive a less profound treatment response compared to BRAF-WT patients. The difference in outcome according to BRAF status is evident after achievement of DpR with BRAF-MT patients hardly deriving any further disease control beyond DpR. Our observations hint towards an aggressive tumor evolution in BRAF-MT tumors, which may already be molecularly detectable at the time of DpR.